Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ABIOMED, Inc.    ABMD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies

Jordan Dufee

 
 
share with twitter share with LinkedIn share with facebook
share via e-mail

Good timing to anticipate a continuation of the trend

Strategy published on 09/12/2017 | 14:28
long trade
Target price hit
Entry price : 158.28$ | Target : 172.75$ | Stop-loss : 150$ | Potential : 9.14%
Shares in ABIOMED, Inc. show a positive technical chart pattern over the medium term. The timing to jump back on the rising trend seems good.
Investors have an opportunity to buy the stock and target the $ 172.75.
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.

Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Predictions on business development from analysts polled by Thomson-Reuters are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The group usually releases upbeat results with huge surprise rates.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 128.58 USD

Weaknesses
  • With an expected P/E ratio at 74.64 and 61.11 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 575 M
EBIT 2018 142 M
Net income 2018 109 M
Finance 2018 316 M
Yield 2018 -
P/E ratio 2018 81,07
P/E ratio 2019 74,21
EV / Sales 2018 14,4x
EV / Sales 2019 11,1x
Capitalization 8 618 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ABIOMED, INC.
Duration : Period : Day
ABIOMED, Inc. Technical Analysis Chart | ABMD | US0036541003 | 4-Traders
Duration : Period : Week
ABIOMED, Inc. Technical Analysis Chart | ABMD | US0036541003 | 4-Traders